Behavioral Healthcare ExecutiveAMA Releases Full Language of New CPT Code for Psychedelic Therapies

Bridging Psychedelic Therapies and Mainstream Healthcare: Are We Ready?

The American Medical Association (AMA) unveils the full language of a novel Current Procedural Terminology (CPT) III code, targeting in-person monitoring and intervention during psychedelic medication therapy, set to be operational from January 1, 2024.

Key Points:

• The new code was approved by AMA in May after a collaborative application by COMPASS Pathways and MAPS Public Benefit Corporation.
• The code will aid in tracking and reporting on the delivery of psychedelic treatments, covering multiple psychedelic compounds and various staffing structures.
• Reporting will be done in one-hour increments and will include a sub-code for non-qualified health professional clinical staff involvement.
• Pending FDA approval, the new code will encompass COMPASS’s COMP360 psilocybin treatment and MAPS’s MDMA-assisted therapy.

Additional Points:

• The COMP360 psilocybin treatment is under late-stage development for treatment-resistant depression.
• The CEO of COMPASS Pathways, Kabir Nath, affirmed the new code’s role in facilitating access to psychedelic therapies for mental health treatment, if approved.

Conclusion:

• The new CPT III code is a significant milestone in integrating psychedelic therapies into mainstream healthcare, promising better tracking and reporting of these interventions and possibly paving the way for broader access to new mental health treatment modalities.

Psychiatry A-Z

• ‘Bigorexia’ is on the Rise — How Can Physicians Help?June 21, 2022
• ‘Ozempic Personality’ and the Psychological Toll of GLP-1sAugust 13, 2024
• ‘Ozempic Personality’: Why You May Not Act Like Yourself on Weight Loss DrugsApril 30, 2024
• ‘Stress-bragging’ Makes You Less LikableJune 11, 2024